As Biopharma Adopts Generative AI, The ‘People Element’ Is Crucial To Success
After a year of hype around generative AI, the question is can it deliver productivity wins for biopharma? Consultants at BCG give insights into successes and failures of early projects and emphasize that putting people first is key to success.
You may also be interested in...
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.
The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.
A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.